A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.
about
Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other CancersForkhead transcription factor FoxF1 interacts with Fanconi anemia protein complexes to promote DNA damage responseHotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands.Pediatric Rhabdomyosarcoma.Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop.Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis.Spindle cell rhabdomyosarcoma of the retroperitoneum: an unusual case developed in a pregnant woman but obscured by pregnancy.Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.Clonality and evolutionary history of rhabdomyosarcomaA versatile modular vector system for rapid combinatorial mammalian geneticsUterine adenosarcomas are mesenchymal neoplasms.Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.Head and Neck Rhabdomyosarcoma: Clinical and Pathologic Characterization of Seven Cases.A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases.Genetics of Bladder Malignant Tumors in ChildhoodClonal relationships between lobular carcinoma in situ and other breast malignanciesMYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.Cancer genomics: why rare is valuable.Rhabdomyoblastic Differentiation in Head and Neck Malignancies Other Than Rhabdomyosarcoma.Massive parallel sequencing in sarcoma pathobiology: state of the art and perspectives.Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials.A review of gigaxonin mutations in giant axonal neuropathy (GAN) and cancer.A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome.Neomorphic mutations create therapeutic challenges in cancer.Molecular diagnostics in the management of rhabdomyosarcoma.Sequencing your genome: your future is here, but are you sure you want to know it?Molecular profiling of sarcomas: new vistas for precision medicine.Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection.The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group.Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.Clinicopathologic analysis of spindle cell/sclerosing rhabdomyosarcoma.A case of primary spindle cell variant of embryonal rhabdomyosarcoma of the prostate.Distinct malignant behaviors of mouse myogenic tumors induced by different oncogenetic lesions.Genomic comparison of early-passage conditionally reprogrammed breast cancer cells to their corresponding primary tumors.The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope.Genomics of adult and pediatric solid tumors
P2860
Q26766271-64253D6E-4413-4F9A-939A-4416921BBBD4Q28270475-BC5C0466-2DA3-4E8F-9796-C21168CCFB24Q30459163-6F8C6C45-9D33-436A-B295-38D2935220CEQ33842070-A5242840-6403-4F38-AFA1-CC7FA0495560Q33872384-18665F3B-1362-493F-B081-0FE16BE54F52Q33940017-2842C6DC-9D1F-4005-80B8-8DF59D46DED6Q34121419-23CBEA95-9EF7-49A1-AF93-98735994DE77Q34508636-54329DAB-6CBA-4412-8516-A1AD5E8FB1B5Q35096201-CD87A530-21A9-4EF7-8162-6517BEECE237Q35175269-EAE39C63-FDB1-4E10-A6AD-87C5236FBD5EQ35408740-FD400241-1EB2-4E77-BEA8-7FCDA95660B6Q35848142-11BA7697-6EC7-474A-8920-31183DE0294AQ35863493-1CC5D7ED-3071-4161-911E-064C07ED4535Q36142754-DA59ACAB-D5AE-444E-BA91-5BD01E8CFB3EQ36206424-183E5B3F-FB20-43FB-8CD2-490F86C86979Q36460093-A281A469-54EB-4428-B656-0C67E7778E8EQ36658484-E668D3E8-043C-4380-B632-BF29230E6FEEQ37031141-348798D3-F873-46C8-9921-25A64EA596A1Q37463719-884BB1E2-479E-47FA-9726-21E6D4AF5F8DQ38353573-66C5D377-AE2D-4A42-B6EE-A473B0A84D50Q38372544-9FA543A9-497F-40B8-859B-AC57421BEF08Q38625070-647E41A5-3706-480B-BEEE-F7166DB3D42EQ38776314-1A34B91A-E2AB-4D4E-9044-52F57BDF9E87Q38792675-D26659C9-2AC8-49A4-81BE-980C9C0ABD6BQ38968621-46555C54-5535-4464-9CD3-A291A274C150Q39007820-D77EAB10-7603-4206-8F96-D18BB43BB64CQ39069676-D9D9F27D-C837-4387-B373-B73BADCBC8F3Q39160024-F95D6DBE-6627-4FDD-9749-5B2C29E6EEF3Q39406356-8AD0AE7E-87FF-4536-875E-BF4A87439D1BQ40498502-6A118341-60E0-4A71-AA90-03C0CA0CCA37Q40923985-4E7AAC67-CE19-4BE4-9E8C-E77D96B72A23Q41073736-DE27FDC2-45BB-4A98-A9D9-EC5B0CCEEECEQ41627789-F0138C89-D690-4DC5-9C72-163816E6CC4AQ42000398-5D23DC01-9374-4141-BA83-9C762727DCBDQ42160737-E1D2397F-669B-4E2C-9F0B-43E5556B341BQ46225087-C21DCF12-280C-4994-8E98-1A5BEF4C06FEQ50067454-E91C133E-E72D-4574-805B-35C2941584BCQ58804574-F6623D0A-C9CB-4B83-BEF9-DF4478024F43
P2860
A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
A recurrent neomorphic mutatio ...... th PI3K-AKT pathway mutations.
@ast
A recurrent neomorphic mutatio ...... th PI3K-AKT pathway mutations.
@en
A recurrent neomorphic mutatio ...... th PI3K-AKT pathway mutations.
@nl
type
label
A recurrent neomorphic mutatio ...... th PI3K-AKT pathway mutations.
@ast
A recurrent neomorphic mutatio ...... th PI3K-AKT pathway mutations.
@en
A recurrent neomorphic mutatio ...... th PI3K-AKT pathway mutations.
@nl
prefLabel
A recurrent neomorphic mutatio ...... th PI3K-AKT pathway mutations.
@ast
A recurrent neomorphic mutatio ...... th PI3K-AKT pathway mutations.
@en
A recurrent neomorphic mutatio ...... th PI3K-AKT pathway mutations.
@nl
P2093
P2860
P50
P356
P1433
P1476
A recurrent neomorphic mutatio ...... th PI3K-AKT pathway mutations.
@en
P2093
Agnes Viale
Angela Marchetti
Frederic G Barr
Jonathan A Fletcher
Julia Bridge
Leonard H Wexler
Li-Xuan Qin
Mono Pirun
P2860
P2888
P304
P356
10.1038/NG.2969
P407
P577
2014-05-04T00:00:00Z